Martin Madaus was appointed Director of Haemonetics Corp. As of November 6, 2026, Haemonetics Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 1, 2026 to July 28, 2026, naming 1 appointment and 1 departure (Form 8-K, July 28, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Haemonetics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Haemonetics Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-01 to 2026-07-28. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Haemonetics Corp files it.
Also on the record for Haemonetics Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 12, 2026 | Stake report, Schedule 13G/A, by AQR Capital Management, LLC | 4.99% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by North Peak Capital Management, LLC | — | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.26% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.59% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 3, 2026 | Stake report, Schedule 13G, by North Peak Capital Management, LLC | 5.1% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G, by AQR Capital Management, LLC | 6.76% of the class | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 4.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Haemonetics Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Haemonetics Corp and the records around it.
Haemonetics Corp elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- North Peak Capital Management, LLC also filed stake reports on 2 other companies: GMR Solutions Inc. (Aug 2026), agilon health, inc. (Nov 2025)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
- Wellington Management Group LLP also filed stake reports on 240 other companies: Hub Group, Inc. (Oct 2026), Latham Group, Inc. (Oct 2026), Redwood Trust, Inc. (Oct 2026)
Watch Haemonetics Corp
Get an email when Haemonetics Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Haemonetics Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Haemonetics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Haemonetics Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-28 | In | Director | 8-K, 2026-07-28 | ||
| 2026-05-01 | Out | 8-K, 2026-05-01 |
Who leads Haemonetics Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Martin Madaus, appointed (filed 2026-07-28).
New leaders reset buying decisions — get the Full Report on Haemonetics Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Haemonetics Corp, with the record behind each one.
Find candidates like Director at Haemonetics CorpEvery change, in the filing's words
Appointed: Martin Madaus, Director
(d) On July 24, 2026, the Board of Directors of Haemonetics Corporation (the "Company") elected Martin Madaus as a director of the Company, effective immediately.
- Dr. Madaus currently serves as Senior Operating Executive at The Carlyle Group, where since 2019 he has advised on healthcare investments and portfolio company performance.
- Dr. Madaus, who will stand for election by shareholders at the Company's 2027 annual meeting of shareholders, is expected to be appointed to serve on the Audit Committee and the Governance and Compliance Committee of the Board of Directors.
- As a non-employee director of the Company, Dr. Madaus will receive compensation as described in the "Directors' Compensation" section of the Company's definitive proxy statement for the 2026 annual meeting of shareholders, with an annual equity award having an approximate value of $200,000.
Departing: Charles J. Dockendorff
On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the "Company") that he will not stand for re-election at the Company's 2026 Annual Meeting of Shareholders (the "2026 Annual Meeting").
- Mr. Dockendorff has served as a member of the Board of Directors (the "Board") of the Company since 2014 and currently serves as a member of the Audit Committee and the Governance and Compliance Committee.
- Mr. Dockendorff will continue to serve as a director and in his committee roles until the 2026 Annual Meeting.
- Mr. Dockendorff's decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with the Company.
Tools for this story
Each opens in a new tab, filled in for Haemonetics Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.